chrisvoncsefalvay/vaers-outcomes huggingface dataset:
8 days after the shot I had an episode of tingling and numbness bilaterally from my feet up to my thighs. I had difficulty walking, a lot of pain and a vibration sensation in my thighs with weakness. I was admitted to the hospital for 3 days and had abnormal neuro reflexes upon admission and severe brain fog, which I have never had before. MRIs and blood work were done in the hospital but they could not determine the cause and the hospital questioned it being from the COVID vaccination and has had me follow up further with specialists to see if there could be any other diagnostic causes. I have followed up with my PCP, 2 neurologists, a rheumatologist, allergist, dermatologist and will be seeing a hematologist.  (I now have joint pains, extreme fatigue, brain fog, peripheral neuropathy--none of which I had prior to the vaccination and thus far conditions outside of the vaccination have not been found. I also got a positive ANA after vaccination (I had negative in the past and my doctors are questioning if the covid vaccination triggered an autoimmune disorder now in me with the joint pain and swelling, fatigue, positive ANA, rashes and pain).  I have been out of work since February due to health impairments and am a healthcare provider myself.
Initial unsolicited report received from the literature on 23-Oct-2017. This case is linked with 2017SA207248, 2017SA207251, 2017SA207263, 2017SA207267, 2017SA207271, 2017SA207273, 2017SA207275, 2017SA207277, 2017SA207279, 2017SA207280, 2017SA207282 (Same reporter). The following is the abstract from the article: Yellow fever vaccine is a live attenuated viral inoculation indicated for patients traveling to endemic areas. The vaccine is generally well tolerated with minimal adverse effects. Typical side effects include malaise, pain at the injection site, and, albeit rarely, immediate hypersensitivity reactions. We present a case of a rare adverse reaction to yellow fever vaccine in which a patient developed vesicular lesions resulting in bullae and circumferential hyperpigmentation. This case involves 11 years old male patient who was vaccinated with first dose of YELLOW FEVER VACCINE (batch number: 1F21057) subcutaneously in right arm, (expiry date was not reported) on 18-Feb-1992. Patient did not have any current Illness other medication and concomitant medication included DEPAKOTE. Preexisting condition was reported seizure disorder. On 25-Feb-1992 seven days post vaccination patient had headache, arm stiff, a small single vesicle occurring at the vaccine injection site, Injection site hypersensitivity and red in a circle the size of a quarter. Laboratory investigation and corrective treatment was not reported. On an unknown date, the patient was recovered from events. List of documents held by sender: none.
Fever of 101, body aches, headache. Onset 10 hours after injection. Managed on ibuprofen.
Syncopal episode 6 minutes after receiving 4 vaccines. Possible tonic due to breath holding-difficult to arouse verbally but responded to sternal rub. Pupils dilated 453; P.O. 99; HR 60; B/P 152/78; 5pm Pulse Ox 99, HR 78, 142/72
Information has been received from a 61 year old female with "thyroid condition", a previous case of shingles years ago when on chemotherapy for cancer (before ZOSTAVAX (Merck) became available) and no drug reactions/allergies who about a year and a half ago (in approximately October 2009) was vaccinated with ZOSTAVAX (Merck) (lot # not reported) at a local pharmacy. Concomitant therapy included unspecified thyroid medication. Approximately ten days ago (approximately on 27-MAR-2011), the patient developed a "case of shingles". The patient's shingles persisted. No lab diagnostics studies were performed. No treatment was given for the event. The patient sought unspecified medical attention. The patient noted she spoke with her pharmacist on 06-APR-2011 and the pharmacist told her "she was not the only one this has happened to." Follow up information has been received from the patient reporting that she had symptoms of pain and sensitivity. After numerous blood tests, it was found that she was immune to the disease. The patient spoke to her pharmacist and the pharmacist told her that she wasn't the only customer that had complain about getting symptoms. This is one of several reports from the same source. Additional information has been requested.
RECD VACCINES MID AFTERNOON 11-12-08. STATES THAT IN THE NIGHT SHE BEGAN HAVING FEVER,CHILLS & PAIN @ INJECTION SITES. ALSO STATES SHE ACHED ALL OVER.ALSO INDICATED SHE HAD LABORED BREATHING. TOOK ASPIRIN FOR FEVER & PAIN.wAS SEEN BY ONE OF THE ACHD PRACTITIONERS.
A physician reported via a company representative that an unidentified child received a total of 4 doses of prevnar (pneumococcal 7-valent conjugate vaccine) (dates of immunization not specified).The child is now diagnosed with bactermia. No additional information was available as of the report. *F/UP report on 3/31/03: Upon further medical review on 1/14/03 case reversioned to code of "bacteremia". This case was serious since this event was considered medically important in this case (OMIC). No add'l info was available as of the date of this report.*
Per spouse "sick with fever for over 24 hours. He ached and had a headache made him restless and unable to sleep. Most body aches were upper body - upper back between shoulder blades". Onset within 12 hours of shot. Spouse reported this on 10/12/12.
ALLERGIC REACTION, SEQUELA 2/4/2023 EPILEPSY, UNSPECIFIED
This case was reported by a pharmacist via call center representative and described the occurrence of injection site itching in a 80-year-old female patient who received SHINGRIX (batch number 3Z4KL, expiry date 30th January 2020). On 15th February 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. In February 2018, several days after receiving SHINGRIX, the patient experienced injection site itching, injection site swelling, injection site erythema and injection site inflammation. On an unknown date, the outcome of the injection site itching, injection site swelling, injection site erythema and injection site inflammation were not recovered/not resolved. The reporter considered the injection site itching, injection site swelling, injection site erythema and injection site inflammation to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX in the left deltoid. The health care professional reported that the patient experienced itching, inflammation, redness, and swelling locally at injection site a few days after receiving the SHINGRIX vaccine. The patient's symptoms had not resolved on the reporting date, but they were not getting worse.
3/23/21 - 8:00 pm day of 2nd dose started fever, chills, body aches, dizziness, nausea, malaise, and headache.  Dizziness was worst while standing, could not walk far distances or stay upright very long.  Fever went as high as 102.5.   Took ibuprofen as directed for fever,/pain, but fever still stayed in the 100-101 range until the morning of 3/26/21.   3/27/21 - currently injection site is red, swollen, and painful to the touch.   Malaise still lingering
Rash started 6/10/06, with low-grade fever 100.7 (+) maculopapular lesions over face, hip area, thighs, scalp some with crusted over areas per MDA. (+) pruritus. Rx: Benadryl 12.5/5ml 2ml po q 8 hrs, Tylenol 160/5ml 4 tsp po q 6 hrs for fever.
Patient reported a painful rash on abdomen the morning after the flu shot. Doctor thought there may have been a connection to getting the flu shot.
Vaccine received at 1400 hrs. on 10/3/17. At 2000 hrs. on 10/3/17, experienced headache, nausea, vertigo, extreme weakness. I needed help even to get out of bed to get to the bathroom. I felt like I was going to  to take me to the walk in clinic, but I felt too terrible to even do that. It lasted for 2 days.
About four hours after immunization patient developed a fever of 102-103. Fever lasted 3-4 hours.  Was unconsolably crying during that time except for when nursing.  Crying lasted greater than 3 hours.
The child was vaccinated with the Pfizer-Child Covid-19 vaccine, everything was mixed correctly.  Unfortunately, we missed calculated the 10-week BUD window and gave the vaccine outside the BUD by Five days.  Spoke to the child parent.
Child has Aspergers.  Shot resulted in ongoing over sensory issues, sensory meltdowns and extreme violence. 10/2/08-records received for DOS 6/3-6/11/08-admitted for behavioral issues and on 6/20-6/26-08 for starting a fire and 8/11/08- for blasting out a window. Developed tremors in hands in May 2008. Diagnosed with Asperger's. Diffuse abdominal pain. Staff feels it is attention getting behavior.
Client received additional (3rd) dose for immunocompromise. Client disclosed to vaccinator, "I am immunocompromised" (Crohn's disease) after administration of full-dose COVID-19 Moderna vaccine. Client completed primary series Pfizer vaccine > 6 months ago.
Patients were administered the Moderna Covid 19 Monovalent booster instead of the bivalent; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patients were administered the Moderna Covid 19 Monovalent booster instead of the bivalent) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR5186C) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (Patients were administered the Moderna Covid 19 Monovalent booster instead of the bivalent) and NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patients were administered the Moderna Covid 19 Monovalent booster instead of the bivalent) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patients were administered the Moderna Covid 19 Monovalent booster instead of the bivalent).    No concomitant medications was reported. No treatment medications was reported.  The reporter would like to know if she can give patients the bivalent booster now or if she should wait. She would like to know what is the procedure in these cases.   This case was linked to US-MODERNATX, INC.-MOD-2022-650927, US-MODERNATX, INC.-MOD-2022-650932 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-650927:Same reporter US-MODERNATX, INC.-MOD-2022-650932:Same reporter
This spontaneous report was received from a medical assistant and refers to a 2 month old patient of unknown gender. The patient's concurrent conditions, medical history or concomitant medications were not reported. On 21-DEC-2015, the patient was vaccinated with VAQTA, 0.5 ml, intramuscularly, lot# L032749, expiry date 04-NOV-2016 (site of administration was not reported). No adverse effects were reported. No product quality complaint (PQC) was involved. Additional information has been requested.
Pt was adminestered a PCV23 per RN who previously spoke to allergist and decided it was ok to give vaccine. Around 5 mons after administration patient started developing a rash on face, and body. Epi was given by RN.
Developed rash in any place on body that I pressed on, rubbed, or scratched. Rash lasts approx 15-30 minutes then goes away. Treated with benedryl, did nothing to prevent or lessen symptoms. Contacted teledoc and was prescribed prednisone 20 mg tablet - 1 tabs by mouth daily in the morning for 5 days on 4/13. Also advised to report to VAERS
symptoms: light headed & syncope episode in which patient hit head on pavement Vitals: BP 93/51 RR 16, Pulse 115 O2 67% Intervention/treatment: Oxygen at 6L/minute by non-rebreather , re-assessed vitals, called for EMS transport O2 Sats after oxygen was 100%. Paramedics assessed patient and took a blood glucose which was 118. Patient denied drug and alcohol usage and denied pregnancy NKDA NDMedical Condition other than anxiety and fear of needles. Patient refused medical transport and signed waiver with Paramedics
Headaches after vaccine; This is a spontaneous report from a Pfizer-sponsored program, General Company Information, received via a contactable  consumer. A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number/expiration date unknown) via an unspecified route of administration on an unspecified date at a single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. The patient experienced headaches after vaccine on an unspecified date. The outcome of the event was unknown.  Information on the lot/batch number has been requested.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site erythema in a adult patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced injection site erythema and injection site warmth. On an unknown date, the outcome of the injection site erythema and injection site warmth were recovered/resolved. It was unknown if the reporter considered the injection site erythema and injection site warmth to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected as adult as per vaccine indication. The healthcare professional (HCP) reported that the patient had redness and warmth at the injection site that last about 1 day and then resolved.
pt noticed that she has a 2 " pink area around the injection site that is getting larger and turning darker pink that developing small spots within this area and now spreading.  Pt has not put any medicine on it at this time.
Swelling of the whole thigh (right) with a red patch 1 1/2" in diameter around the site of the injection; itchy. The thigh felt warmer than the other thigh.
fever 101-102;screaming/crying picked up, stiff body;twitching jerking x 7;weird look on face;non responsive, fell asleep;Ibuprofen given-afeb-acting OK;
Donated blood on 2/10/2021 . Received letter in March advising that I tested positive for Hep C antibody. No known recent exposure to any blood or other infectious agents. Tested negative for Hep C antibody in November 2020 after blood donation. Concern for crossreactivity of SARS-CoV-2 vaccine antibody with Hep C antibody on ELISA test.
pt recv vax in 1991 & 1993 pt  rubeola titer was neg; f/u blood testing showed no detectable antibodies; No further info was provided;
pt recv vax & approx 24hr post vax pt devel abd discomfort;
No further AE' reported; Nurse reporting administration of an expired dose of ROTATEQ. Dose was administered today (01Apr2022) and expired on 29Mar2022.; HCP reports this lot # of ROTATEQ has undergone a temperature excursion.; This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 01-APR-2022, the patient was administered an expired and improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral liquid, 2 ml one time, lot #1707496, expiration date: 29-MAR-2022 (dose number and route of administration were not provided) administered for prophylaxis  (expired product administered, product storage error). Administered dose of vaccine experienced the temperature excursion of 57.0 degrees Fahrenheit for 3 hours. No further adverse events (AE's) were reported.
Dec 2nd my daughter complained of lower leg pain.  After sleeping 5 hours she woke with both lower legs completely numb.  We went to her pediatrican who thought she had GBS and sent us to a pedi neurologist.  She had tingling before the next upper part of her body would go numb.  By Friday AM she was numb from the waist down.  Neurologist had her admitted to the hospital.  They did tests and eventually did the spinal tap on the 6th day as the feeling was beginning to return in her legs.  The numbness made it way up to get below her chest and the tingling was from her chest to her head.  She spent 6 days in the hospital.  She didn't return to school until January and even then her legs would still be painful when she became too tired.  Her cheeks and ears become red and then she starts to complain about her legs hurting.  She hasn't complained about her legs now in about 2 weeks. 60 Day Follow up: When she becomes really tired her cheeks and ears become bright red. If the tiredness is extreme then her legs and arms will start tingling and hurting. Information received from annual follow up letter states when really tired, patient's ears and sometimes cheeks turn red.
Fiscally noticed that a rash that was caused by the medicine went away; White blood cell count increased; Platelet count increased; This spontaneous case was reported by a consumer and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (Fiscally noticed that a rash that was caused by the medicine went away), WHITE BLOOD CELL COUNT INCREASED (White blood cell count increased) and PLATELET COUNT INCREASED (Platelet count increased) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030L20A and 030L20A) for COVID-19 vaccination.     Concurrent medical conditions included Chronic myeloid leukemia since 20-Jun-2000 and Rash. Concomitant products included IMATINIB for Leukaemia, ACETYLSALICYLIC ACID (BABY ASPIRIN), LOSARTAN, TORSEMIDE, ATORVASTATIN and ALLOPURINOL for an unknown indication.   On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (Fiscally noticed that a rash that was caused by the medicine went away), WHITE BLOOD CELL COUNT INCREASED (White blood cell count increased) and PLATELET COUNT INCREASED (Platelet count increased). At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (Fiscally noticed that a rash that was caused by the medicine went away) had resolved and WHITE BLOOD CELL COUNT INCREASED (White blood cell count increased) and PLATELET COUNT INCREASED (Platelet count increased) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Philadelphia chromosome positive: inconclusive (Inconclusive) measures bad white cells. On an unknown date, Platelet count: high (High) High. On an unknown date, White blood cell count: increased (High) Increased white cells by 20% after two weeks from second dose.         Patient had event after increasing dose of imatinib  from 300 mg to 400 mg. Increase was on 01 June. Patient had another blood test and complete BCR-ABL to check defective blood cells and result by 20 July.  Action taken with mRNA-1273 in response to the event was not applicable  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   This case was linked to MOD-2021-233328 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 15-Jul-2021: Follow up received on 15-JUL-2021 and does not contain any new information.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
The vaccine overstimulated my thyroid, which produced chemicals, creating sever tachycardia producing 170 BPM's. When my bloodwork was tested, my thyroid levels were over doubled the limits. I also had high blood pressure. Four days after receiving the vaccine I went to the hospital because I was experiencing a fast heart rate, I was extremely shaky (to where I could hardly stand) and I was having trouble breathing. After multiple tests at the hospital, the conclusion is that I have to let all of the thyroid hormones leave my body. So, basically, I'm just waiting.
Considerable redness, swelling and "heat" at the injection site... discomfort/pain under the arm (lymph area) extending to the chest. Per NP that pt saw she believes that the pain and swelling is all related to the injection.
I had chronic cough, intense sneezing, runny nose, nausea, low grade fever, extreme fatigue, and I lost my sense of smell. I still have not regain my smell. The next day on 08/05/2021 I went to the doctor. They did the rapid COVID test because I requested it. Before the result came back the doctor said I just had a sinus infection and prescribed an antibiotic. Then, the results came back and they were positive. And he told me to take the antibiotic any way. I took it upon myself to take the steroid prescribed for COVID. I am still using Mucinex every day to try to clear up the congestion. The doctor did not offer me anything to try to recover.
shingles; severe rash on his right side(leg,pubic area,stomach area,back area,); painful rash only when touched; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (shingles), RASH (severe rash on his right side(leg,pubic area,stomach area,back area,)) and RASH (painful rash only when touched) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012M20A) for COVID-19 vaccination.     Concurrent medical conditions included Benign prostatic hypertrophy and Emphysema since March 2018. Concomitant products included ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) from 28-Feb-2021 to an unknown date and TRAMADOL from 28-Feb-2021 to an unknown date for Back injury, FINASTERIDE for Benign prostatic hyperplasia, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE, VILANTEROL TRIFENATATE (TRELEGY ELLIPTA) for an unknown indication.   On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-Mar-2021, the patient experienced RASH (severe rash on his right side(leg,pubic area,stomach area,back area,)) and RASH (painful rash only when touched). On an unknown date, the patient experienced HERPES ZOSTER (shingles). At the time of the report, HERPES ZOSTER (shingles) outcome was unknown and RASH (severe rash on his right side(leg,pubic area,stomach area,back area,)) and RASH (painful rash only when touched) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Most recent FOLLOW-UP information incorporated above includes: On 26-May-2021: Updated patient medical history ( Emphysema) and added event (shingles)
This spontaneous report as received from a certified medical assistant refers to a patient of unknown age and gender. No information on patient's medical history, concurrent conditions or concomitant drugs was provided. On an unknown date in 2014 the patient was intramuscularly vaccinated with GARDASIL, dose, route, site of injection, lot# and expiration date not reported. It was reported that on an unspecified date in 2014 (reported as "within the last month"), prior to vaccination of the patient, the GARDASIL was improperly stored at 34F for 70 minutes. There were no known adverse effects. Additional information has been requested.